BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Medicis Pharmaceutical (MRX) And BioMarin Pharmaceutical Inc. (BMRN) Amend License Agreement For Ascent Pediatrics And Orapred


10/19/2005 5:12:12 PM

Medicis Pharmaceutical Corp. on Wednesday said it agreed to amend its May 2004 license agreement with BioMarin Pharmaceutical Inc. The changes will not affect the company's 2005 outlook, the drug maker said. The new deal cuts the amount Medicis will receive from BioMarin to $159 million from $175 million. License payments to be made after July for the asthma therapy Orapred will be cut to $88.4 million from $93 million; and a 2009 payment relating to the purchase of outstanding shares of Ascent Pediatrics will be reduced to $70.6 million from $82 million. The company said it will take over contingent payments due to former Ascent Pediatric shareholders without the $5 million that would have been paid by BioMarin to Medicis after July 1. Also, Medicis said it will give BioMarin a convertible note worth up to $25 million starting July 1, contingent on certain conditions including a change of control provision. The note matures in 2009.

Read at AP
Read at BioSpace.com

AP
BioSpace.com
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES